Biorestorative (BRTX) Fundamental Analysis: Revenue, Earnings & Valuation

1.42 / 10

Underperform

Fundamental rating is Underperform with a 1.4/10 quality score. Key weaknesses include negative YoY revenue growth (-4.92%), low accounts receivable turnover (3.37), adverse income‑tax ratio, and modest asset‑MV. PB‑ROE shows some upside, but overall outlook remains defensive.

Analysis Checks(5/10)

Revenue-MV

Value-5.58

Score1/3

Weight32.20%

1M Return5.06%

Total operating revenue (YoY growth rate %)

Value-4.92

Score1/3

Weight-7.40%

1M Return-1.40%

Inventory turnover ratio

Value47.57

Score3/3

Weight-3.45%

1M Return-0.67%

Accounts receivable turnover ratio

Value3.37

Score1/3

Weight-8.59%

1M Return-1.57%

PB-ROE

Value0.84

Score2/3

Weight68.10%

1M Return8.98%

Income tax / Total profit (%)

Value-5.52

Score0/3

Weight-7.76%

1M Return-1.54%

Fixed assets turnover ratio

Value1.01

Score2/3

Weight-5.45%

1M Return-1.01%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-3.85%

1M Return-0.73%

Cost of sales ratio (%)

Value6.53

Score3/3

Weight4.80%

1M Return0.79%

Asset-MV

Value-0.48

Score0/3

Weight31.41%

1M Return4.88%

Is BRTX undervalued or overvalued?

BRTX scores 1.42/10 on fundamentals and holds a Premium valuation at present. Backed by its -205.51% ROE, -3959.40% net margin, -0.53 P/E ratio, 21.14 P/B ratio, and -36.21% earnings growth, these metrics solidify its Underperform investment rating.